At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Multicenter, Phase 2 Study of Retifanlimab in Combination With INCAGN02385 (Anti-LAG-3) and INCAGN02390 (Anti-TIM-3) as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
In Brief
A Phase 2 clinical trial evaluating Retifanlimab, INCAGN02385, and 2 other interventions for Head and Neck Cancer. Active but no longer recruiting, targeting 176 participants across 91 sites in 14 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).
Study Details
Timeline
Interventions
Retifanlimab 500mg will be administered intravenously every 4 weeks.
INCAGN02385 350mg will be administered intravenously every 2 weeks.
INCAGN02390 400 mg will be administered intravenously every 2 weeks.
Placebo will be administered intravenously.